No Data
Huadong Medicine (000963.SZ): The clinical trial application for the HDM2006 pharmaceutical has received approval from the USA FDA.
On January 13th, Glorunhui reported that Huadong Medicine (000963.SZ) announced that on January 10, 2025, its wholly-owned subsidiary Hangzhou Sino-American Huadong Pharmaceutical Co., Ltd. received notification from the USA Food and Drug Administration. The clinical trial application for the HDM2006 tablet, submitted by Sino-American Huadong, has been approved by the USA FDA to conduct Phase I clinical trials for the indication of advanced malignant tumors. The HDM2006 tablet is independently developed by Sino-American Huadong targeting HPK1 (Hematopoietic Progenitor Kinase-1).
Sinolink: The market's attention to the left reversal of the pharmaceutical sector is increasing, with a focus on the related Sector of respiratory infections.
The proportion of influenza and other respiratory infections continues to rise, and it is recommended to closely monitor the infectious disease situation.
Sinolink: Major policies have been released, innovation remains the most important direction. The pharmaceutical and healthcare Industry has entered a performance window, focusing on reversal expectations.
The market has entered the window period for annual and quarterly reports, and it is recommended to actively pay attention to the fundamental Bearish clearance of left-side symbols (such as some Medical Devices, Traditional Chinese Medicine, pharmacies, chain Medical, CXO, etc.) and the implementation of centralized procurement policies.
Huadong Medicine Subsidiary Gets Aproval for HDM1005 Weight Management Drug Clinical Trials
Here's Why Huadong Medicine (SZSE:000963) Can Manage Its Debt Responsibly
Huadong Medicine (000963.SZ): The HDM1005 injection from Sino-American Huadong has been approved for clinical trials.
On January 2, Gelonghui reported that Huadong Medicine (000963.SZ) announced that on December 31, 2024, its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (referred to as "Zhongmei Huadong") received the "Clinical Trial Approval Notification" issued by the National Medical Products Administration (NMPA) (notification numbers: 2024LP03036 and 2024LP03037). The clinical trial application for HDM1005 injection submitted by Zhongmei Huadong has been approved. HDM1005 injection is developed and owned by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Fewer Investors Than Expected Jumping On Huadong Medicine Co., Ltd (SZSE:000963)
